After adjustment for potential confounders, prostate cancer patients with the TIMP3 rs9619311 polymorphism homozygous for TC and TC + CC had a 1.730-fold (95% CI: 1.035–2.892; p = 0.036) and 1.743-fold (95% CI: 1.044–2.910; p = 0.033) higher risk of biochemical recurrence compared with those with TT homozygous. This evidence concerns the gene TIMP3 and prostate carcinoma.